NCT02007772已完成不适用
Effectiveness of TNI (Nasal High-flow) vs. BiPAP (Biphasic Positive Airway Pressure) in Chronic Global Insufficiency in COPD (Chronic Obstructive Pulmonary Disease) Patients
University of Leipzig14 个研究点 分布在 1 个国家目标入组 105 人开始时间: 2011年6月1日最近更新:
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 105
- 试验地点
- 14
- 主要终点
- difference in capillary CO2 carbon dioxide
研究概览
简要总结
The purpose of this trial ist to investigate the difference of the efficacy of two systems for breath support in patients with COPD.
详细描述
The trial consists of 12 weeks of therapy that is divided into two sections. In the first 6-week section patients receive treatment with either TNI or BiPAP and in the second 6-week section treatment is changed. The starting therapy is allocated to the patients via randomisation and should be started directly after the baseline visit.
The treatment and the follow-up period end with the second visit after the second treatment section and the patient decides which device he/she wants to use further.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •presence of COPD with chronic respiratory global insufficiency
- •chronic day-hypercapnia with pCO2 >= 50 mmHg and typical symptoms of ventilatory insufficiency OR patients with exacerbation (after abate of acute symptomatology) with documented hypercapnia >= 50 mmHG on preliminary findings
- •age 18 or older
- •the patient or caretaker must be able to operate the device after a specific training
- •patient must be willing to use the nHF-/BiPAP-device for the whole trial period for at least 5 hours/day
- •patient must be able to answer the questionnaires
- •written informed consent is obtained
排除标准
- •presence of acute respiratory insufficiency
- •exacerbation of type I or II in the last 4 weeks
- •conservative therapy including long-term oxygen therapy according to GOLD update 2011 is not exhausted
- •previous treatment with NIV (non-invasive ventilation) in the last 14 days
- •clinical instability or acute illness (e.g. acute myocardial infarction, tachycardial atrial fibrillation)
- •signs of cardial decompensation (e.g. edema in the lower limbs, pleural effusion)
- •other serious concomitant diseases, the assessment of eligibility is at the discretion of the investigator
- •contraindications for NIV
- •anamnestic suspicion or proven obstructive sleep apnea (OSA)
- •relevant systemic infections, assessment of eligibility is at the discretion of the investigator
- •BMI > 30
- •other additional pulmonary diseases of other genesis or diseases that affect breathing (e.g. mucoviscidosis, scoliosis, muscular diseases)
- •lack of compliance
- •participation in other interventional trials at the same time
- •pregnant or nursing women
- •fertile female patients without effective contraceptive measures during trial participation
研究组 & 干预措施
BiPAP breathing support
Active Comparator
BiPAP is used over a period of 6 weeks (outpatient)
干预措施: nHF (Device)
BiPAP breathing support
Active Comparator
BiPAP is used over a period of 6 weeks (outpatient)
干预措施: BiPAP (Device)
nHF / TNI breathing support
Experimental
nasal high-flow is used over a period of 6 weeks (outpatient)
干预措施: nHF (Device)
nHF / TNI breathing support
Experimental
nasal high-flow is used over a period of 6 weeks (outpatient)
干预措施: BiPAP (Device)
结局指标
主要结局
difference in capillary CO2 carbon dioxide
时间窗: Baseline, 6 weeks, 12 weeks
The primary endpoint is the difference of the capillary pC02 between the treatment with nasal high-flow compared with the baseline value.
次要结局
- difference of the absolute change of HCO3- (hydrogen carbonate / bicarbonate) compared with baseline(baseline, 6 weeks, 12 weeks)
- frequency of occurrence of normocapnia after intervention(Baseline, 6 weeks, 12 weeks)
- difference of the relative and absolute change of capillary pCO2 compared with baseline(Baseline, 6 weeks, 12 weeks)
- difference of the values of base excess after treatment with nHF (nasal high-flow) and of base excess after treatment with BiPAP(baseline, 6 weeks, 12 weeks)
- difference of HCO3- after treatment with nHF and of HC03- after treatment with BiPAP(baseline, 6 weeks, 12 weeks)
- difference of the absolute change of SaO2 (arterial oxygen saturation) compared with baseline(Baseline, 6 weeks, 12 weeks)
- difference of P0,1 after treatment with nHF and of P0,1 after treatment with BiPAP(baseline, 6 weeks, 12 weeks)
- difference of the absolute change of the results of the 6-minutes walking test compared with baseline(baseline, 6 weeks, 12 weeks)
- difference of the absolute change of the disease-specific quality of life compared to baseline(baseline, 6 weeks, 12 weeks)
- difference of the time both devices were used(baseline, 6 weeks, 12 weeks)
- difference in absolute change of capillary pCO2 (partial pressure of carbon dioxide ) compared with baseline(Baseline, 6 weeks, 12 weeks)
- difference of the absolute and relative change of base excess compared with baseline(Baseline, 6 weeks, 12 weeks)
- difference of P0,1/PImax after treatment with nHF and of P0,1/PImax after treatment with BiPAP(baseline, 6 weeks, 12 weeks)
- frequency of occurrence and type of adverse events under trial therapy (both arms)(baseline, 6 weeks, 12 weeks)
- difference of the values of user-friendliness of both devices(baseline, 6 weeks, 12 weeks)
- difference of PImax after treatment with nHF and of PImax (maximal inspiratory pressure) after treatment with BiPAP(baseline, 6 weeks, 12 weeks)
研究者
Jens Bräunlich, MD
Dr. Jens Braeunlich
University of Leipzig
研究点 (14)
Loading locations...
相似试验
Unknown
不适用
NIPPV and nBiPAP Methods in Preterm Infants With Respiratory Distress SyndromeRespiratory Distress SyndromePrematurityNCT02901652Zekai Tahir Burak Women's Health Research and Education Hospital325
招募中
2 期
Effect of budesonide, montelukast and their combination in allergic rhinitisAllergic rhinitis.Vasomotor and allergic rhinitisIRCT20171030037093N41Esfahan University of Medical Sciences135
已完成
2 期
Comparison of intranasal midazolam and ketamine in peripheral IV access in childrePain and distress associated with peripheral IV access in children in emergency department.IRCT20200728048242N1Iran University of Medical Sciences100
Unknown
不适用
Bi-level Positive Airway Pressure for Respiratory Distress Syndrome in Twins InfantsRespiratory Distress SyndromenCPAPBiPAPNCT03235661Daping Hospital and the Research Institute of Surgery of the Third Military Medical University300
尚未招募
不适用
A clinical trial to compare the effect of a non invasive breathing support modality, high flow nasal cannula against conventional oxygen delivery equipments in preventing patients going back to ventilator after taking them off from it.CTRI/2021/09/036985arayana Hrudalaya Hospital